Drug Name:
CORZIDE Rx
Generic Name and Formulations:
Nadolol, bendroflumethiazide; 40mg/5mg, 80mg/5mg; scored tabs.
Company:
Pfizer Inc.
Therapeutic Use:
Indications for CORZIDE:
Hypertension.
Adult:
Titrate components. Renally impaired: increase dosing interval; see literature.
Children:
Not recommended.
Contraindications:
Asthma. Sinus bradycardia. 2nd- or 3rd-degree AV block. Overt heart failure. CHF. Cardiogenic shock. Anuria. Sulfonamide allergy.
Warnings/Precautions:
Ischemic heart disease. Bronchospastic disease, COPD. Renal or hepatic dysfunction. Gout. Diabetes. Postsympathectomy. Hyperthyroidism. Monitor electrolytes, renal function. Surgery. SLE. Avoid abrupt cessation. Pregnancy (Cat.C). Nursing mothers: not recommended.
Pharmacological Class:
Noncardioselective beta-blocker + diuretic.
Interactions:
Hypotension with alcohol, CNS depressants, MAOIs, prazosin, other antihypertensives. Bradycardia with catecholamine-depleting drugs. Adjust antidiabetic, anticoagulant medication. ACTH, amphotericin B, corticosteroids increase hypokalemia risk. May increase toxicity of diazoxide, digitalis, lithium, verapamil, lidocaine. Antagonized by NSAIDs. Antagonizes methenamine, antigout drugs. May block epinephrine. May interfere with glaucoma, parathyroid screening tests.
Adverse Reactions:
Cardiac failure, bronchospasm, bradycardia, heart block, fatigue, fluid and electrolyte imbalance, orthostatic hypotension, GI upset, dizziness, blurred vision, cold extremities, rash, pruritus, blood dyscrasias.
How Supplied:
Tabs—100
Sign Up for Free e-newsletters
ONA Articles
- FDA: Number of U.S. Women With Breast Implant-Caused Cancer Has Increased
- Takeda to Collaborate With MSKCC on CAR-T Therapies for Multiple Myeloma
- Sequential Immunotherapy, Targeted Therapy Linked to Cutaneous Adverse Events in Advanced Melanoma
- Immunotherapy for HER2-positive Breast Cancer: Recent Advances and Combination Therapeutic Approaches
- NIH Establishes Educational Program on Genomics, Genetics for Oncology Nurses
- Oncology Nurse Navigation Facilitates Timely Treatment of Pancreatic Cancer
- Helping Patients Face the Challenge of Eating Healthy During Cancer Treatment
- Oncology Nurses Weigh In on Their Patient-Centered Communication Practices, Needs
- Substitute for Lidocaine
- CART cell therapy for prostate cancer: status and promise
- Immunotherapy for HER2-positive Breast Cancer: Recent Advances and Combination Therapeutic Approaches
- Survey Demonstrates Relationship Between Symptom Burden, Medical Disability Leave Among Myeloproliferative Neoplasms
- A Review of Clinical Outcomes in Patients With Early-Stage Burkitt Lymphoma
- FDA: Number of U.S. Women With Breast Implant-Caused Cancer Has Increased
- USPSTF Still Recommends Against Pancreatic Cancer Screening
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Genitourinary Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Rare Cancers | Regimens | |
| Skin Cancer | Regimens | Drugs |